Proteins > Sodium/glucose cotransporter 2
Page last updated: 2024-08-07 16:28:47
Sodium/glucose cotransporter 2
A sodium/glucose cotransporter 2 that is encoded in the genome of human. [PRO:DNx, UniProtKB:P31639]
Synonyms
Na(+)/glucose cotransporter 2;
Low affinity sodium-glucose cotransporter;
Solute carrier family 5 member 2
Research
Bioassay Publications (48)
Timeframe | Studies on this Protein(%) | All Drugs % |
pre-1990 | 0 (0.00) | 18.7374 |
1990's | 0 (0.00) | 18.2507 |
2000's | 7 (14.58) | 29.6817 |
2010's | 35 (72.92) | 24.3611 |
2020's | 6 (12.50) | 2.80 |
Compounds (15)
Drugs with Inhibition Measurements
Drugs with Activation Measurements
5,5-Difluoro- and 5-Fluoro-5-methyl-hexose-based C-Glucosides as potent and orally bioavailable SGLT1 and SGLT2 dual inhibitors.Bioorganic & medicinal chemistry letters, , 09-01, Volume: 30, Issue:17, 2020
The Druggability of Solute Carriers.Journal of medicinal chemistry, , 04-23, Volume: 63, Issue:8, 2020
Synthetic strategy and SAR studies of C-glucoside heteroaryls as SGLT2 inhibitor: A review.European journal of medicinal chemistry, , Dec-15, Volume: 184, 2019
Identification of an oxime-containing C-glucosylarene as a potential inhibitor of sodium-dependent glucose co-transporter 2.European journal of medicinal chemistry, , Jan-01, Volume: 143, 2018
Targeting Type 2 Diabetes with C-Glucosyl Dihydrochalcones as Selective Sodium Glucose Co-Transporter 2 (SGLT2) Inhibitors: Synthesis and Biological Evaluation.Journal of medicinal chemistry, , 01-26, Volume: 60, Issue:2, 2017
N-Indolylglycosides bearing modifications at the glucose C6-position as sodium-dependent glucose co-transporter 2 inhibitors.Bioorganic & medicinal chemistry, , 05-15, Volume: 24, Issue:10, 2016
Synthesis of novel l-rhamnose derived acyclic C-nucleosides with substituted 1,2,3-triazole core as potent sodium-glucose co-transporter (SGLT) inhibitors.Bioorganic & medicinal chemistry letters, , Mar-15, Volume: 24, Issue:6, 2014
Synthesis and biological evaluation of novel C-aryl d-glucofuranosides as sodium-dependent glucose co-transporter 2 inhibitors.Bioorganic & medicinal chemistry, , Nov-01, Volume: 21, Issue:21, 2013
C-Aryl 5a-carba-β-d-glucopyranosides as novel sodium glucose cotransporter 2 (SGLT2) inhibitors for the treatment of type 2 diabetes.Bioorganic & medicinal chemistry, , Jul-01, Volume: 20, Issue:13, 2012
Structure-activity relationship studies of 4-benzyl-1H-pyrazol-3-yl β-d-glucopyranoside derivatives as potent and selective sodium glucose co-transporter 1 (SGLT1) inhibitors with therapeutic activity on postprandial hyperglycemia.Bioorganic & medicinal chemistry, , Nov-15, Volume: 20, Issue:22, 2012
Discovery of tofogliflozin, a novel C-arylglucoside with an O-spiroketal ring system, as a highly selective sodium glucose cotransporter 2 (SGLT2) inhibitor for the treatment of type 2 diabetes.Journal of medicinal chemistry, , Sep-13, Volume: 55, Issue:17, 2012
Discovery of non-glucoside SGLT2 inhibitors.Bioorganic & medicinal chemistry letters, , Apr-15, Volume: 21, Issue:8, 2011
Discovery of novel N-β-D-xylosylindole derivatives as sodium-dependent glucose cotransporter 2 (SGLT2) inhibitors for the management of hyperglycemia in diabetes.Journal of medicinal chemistry, , Jan-13, Volume: 54, Issue:1, 2011
(1S)-1,5-anhydro-1-[5-(4-ethoxybenzyl)-2-methoxy-4-methylphenyl]-1-thio-D-glucitol (TS-071) is a potent, selective sodium-dependent glucose cotransporter 2 (SGLT2) inhibitor for type 2 diabetes treatment.Journal of medicinal chemistry, , Apr-22, Volume: 53, Issue:8, 2010
Alstiphyllanines E-H, picraline and ajmaline-type alkaloids from Alstonia macrophylla inhibiting sodium glucose cotransporter.Bioorganic & medicinal chemistry, , Mar-15, Volume: 18, Issue:6, 2010
Development of the renal glucose reabsorption inhibitors: a new mechanism for the pharmacotherapy of diabetes mellitus type 2.Journal of medicinal chemistry, , Apr-09, Volume: 52, Issue:7, 2009
Design and synthesis of fluorescent SGLT2 inhibitors.Bioorganic & medicinal chemistry letters, , Sep-15, Volume: 18, Issue:18, 2008
Discovery of dapagliflozin: a potent, selective renal sodium-dependent glucose cotransporter 2 (SGLT2) inhibitor for the treatment of type 2 diabetes.Journal of medicinal chemistry, , Mar-13, Volume: 51, Issue:5, 2008
Aglycone exploration of C-arylglucoside inhibitors of renal sodium-dependent glucose transporter SGLT2.Bioorganic & medicinal chemistry letters, , Sep-01, Volume: 18, Issue:17, 2008
Na+-glucose cotransporter (SGLT) inhibitory flavonoids from the roots of Sophora flavescens.Bioorganic & medicinal chemistry, , May-15, Volume: 15, Issue:10, 2007
Sodium-Glucose Cotransporter Inhibitors as Antidiabetic Drugs: Current Development and Future Perspectives.Journal of medicinal chemistry, , 08-25, Volume: 65, Issue:16, 2022
C-Aryl 5a-carba-β-d-glucopyranosides as novel sodium glucose cotransporter 2 (SGLT2) inhibitors for the treatment of type 2 diabetes.Bioorganic & medicinal chemistry, , Jul-01, Volume: 20, Issue:13, 2012
Discovery of GCC5694A: A potent and selective sodium glucose co-transporter 2 inhibitor for the treatment of type 2 diabetes.Bioorganic & medicinal chemistry letters, , 01-15, Volume: 56, 2022
The Race to Bash NASH: Emerging Targets and Drug Development in a Complex Liver Disease.Journal of medicinal chemistry, , 05-28, Volume: 63, Issue:10, 2020
Design, synthesis and biological evaluation of 6-deoxy O-spiroketal C-arylglucosides as novel renal sodium-dependent glucose cotransporter 2 (SGLT2) inhibitors for the treatment of type 2 diabetes.European journal of medicinal chemistry, , Oct-15, Volume: 180, 2019
Synthetic strategy and SAR studies of C-glucoside heteroaryls as SGLT2 inhibitor: A review.European journal of medicinal chemistry, , Dec-15, Volume: 184, 2019
Synthesis and biological evaluation of 6-hydroxyl C-aryl glucoside derivatives as novel sodium glucose co-transporter 2 (SGLT2) inhibitors.Bioorganic & medicinal chemistry letters, , 07-01, Volume: 28, Issue:12, 2018
Design, synthesis and biological evaluation of nitric oxide releasing derivatives of dapagliflozin as potential anti-diabetic and anti-thrombotic agents.Bioorganic & medicinal chemistry, , 08-07, Volume: 26, Issue:14, 2018
Identification of an oxime-containing C-glucosylarene as a potential inhibitor of sodium-dependent glucose co-transporter 2.European journal of medicinal chemistry, , Jan-01, Volume: 143, 2018
Targeting Type 2 Diabetes with C-Glucosyl Dihydrochalcones as Selective Sodium Glucose Co-Transporter 2 (SGLT2) Inhibitors: Synthesis and Biological Evaluation.Journal of medicinal chemistry, , 01-26, Volume: 60, Issue:2, 2017
Discovery of a Potent, Selective Renal Sodium-Dependent Glucose Cotransporter 2 (SGLT2) Inhibitor (HSK0935) for the Treatment of Type 2 Diabetes.Journal of medicinal chemistry, , 05-25, Volume: 60, Issue:10, 2017
Transporter-mediated tissue targeting of therapeutic molecules in drug discovery.Bioorganic & medicinal chemistry letters, , Mar-01, Volume: 25, Issue:5, 2015
The design and synthesis of novel SGLT2 inhibitors: C-glycosides with benzyltriazolopyridinone and phenylhydantoin as the aglycone moieties.Bioorganic & medicinal chemistry, , Jul-01, Volume: 22, Issue:13, 2014
Synthesis of novel l-rhamnose derived acyclic C-nucleosides with substituted 1,2,3-triazole core as potent sodium-glucose co-transporter (SGLT) inhibitors.Bioorganic & medicinal chemistry letters, , Mar-15, Volume: 24, Issue:6, 2014
Design, synthesis, and biological evaluation of deuterated C-aryl glycoside as a potent and long-acting renal sodium-dependent glucose cotransporter 2 inhibitor for the treatment of type 2 diabetes.Journal of medicinal chemistry, , Feb-27, Volume: 57, Issue:4, 2014
Discovery of tofogliflozin, a novel C-arylglucoside with an O-spiroketal ring system, as a highly selective sodium glucose cotransporter 2 (SGLT2) inhibitor for the treatment of type 2 diabetes.Journal of medicinal chemistry, , Sep-13, Volume: 55, Issue:17, 2012
Synthesis and biological evaluation of novel C-indolylxylosides as sodium-dependent glucose co-transporter 2 inhibitors.European journal of medicinal chemistry, , Volume: 55, 2012
C-Aryl 5a-carba-β-d-glucopyranosides as novel sodium glucose cotransporter 2 (SGLT2) inhibitors for the treatment of type 2 diabetes.Bioorganic & medicinal chemistry, , Jul-01, Volume: 20, Issue:13, 2012
Discovery of non-glucoside SGLT2 inhibitors.Bioorganic & medicinal chemistry letters, , Apr-15, Volume: 21, Issue:8, 2011
Discovery of novel N-β-D-xylosylindole derivatives as sodium-dependent glucose cotransporter 2 (SGLT2) inhibitors for the management of hyperglycemia in diabetes.Journal of medicinal chemistry, , Jan-13, Volume: 54, Issue:1, 2011
Thiazolylmethyl ortho-substituted phenyl glucoside library as novel C-aryl glucoside SGLT2 inhibitors.European journal of medicinal chemistry, , Volume: 46, Issue:7, 2011
Novel thiophenyl C-aryl glucoside SGLT2 inhibitors as potential antidiabetic agents.Bioorganic & medicinal chemistry, , Oct-01, Volume: 19, Issue:19, 2011
Optimization of triazoles as novel and potent nonphlorizin SGLT2 inhibitors.Bioorganic & medicinal chemistry letters, , Jun-15, Volume: 21, Issue:12, 2011
Exploration of SAR regarding glucose moiety in novel C-aryl glucoside inhibitors of SGLT2.Bioorganic & medicinal chemistry letters, , Jan-15, Volume: 21, Issue:2, 2011
Synthesis and SAR of Thiazolylmethylphenyl Glucoside as Novel C-Aryl Glucoside SGLT2 Inhibitors.ACS medicinal chemistry letters, , Feb-10, Volume: 2, Issue:2, 2011
Novel macrocyclic C-aryl glucoside SGLT2 inhibitors as potential antidiabetic agents.Bioorganic & medicinal chemistry, , Sep-15, Volume: 19, Issue:18, 2011
Synthesis of pyridazine and thiazole analogs as SGLT2 inhibitors.Bioorganic & medicinal chemistry, , Aug-15, Volume: 18, Issue:16, 2010
ortho-Substituted C-aryl glucosides as highly potent and selective renal sodium-dependent glucose co-transporter 2 (SGLT2) inhibitors.Bioorganic & medicinal chemistry, , Jun-15, Volume: 18, Issue:12, 2010
Novel C-aryl glucoside SGLT2 inhibitors as potential antidiabetic agents: 1,3,4-Thiadiazolylmethylphenyl glucoside congeners.Bioorganic & medicinal chemistry, , Mar-15, Volume: 18, Issue:6, 2010
C-Aryl glycoside inhibitors of SGLT2: Exploration of sugar modifications including C-5 spirocyclization.Bioorganic & medicinal chemistry letters, , Mar-01, Volume: 20, Issue:5, 2010
Pyrimidinylmethylphenyl glucoside as novel C-aryl glucoside SGLT2 inhibitors.Bioorganic & medicinal chemistry letters, , Dec-01, Volume: 20, Issue:23, 2010
Novel C-aryl glucoside SGLT2 inhibitors as potential antidiabetic agents: Pyridazinylmethylphenyl glucoside congeners.Bioorganic & medicinal chemistry letters, , Jun-01, Volume: 20, Issue:11, 2010
O-Spiro C-aryl glucosides as novel sodium-dependent glucose co-transporter 2 (SGLT2) inhibitors.Bioorganic & medicinal chemistry letters, , Oct-01, Volume: 19, Issue:19, 2009
Exploration of O-spiroketal C-arylglucosides as novel and selective renal sodium-dependent glucose co-transporter 2 (SGLT2) inhibitors.Bioorganic & medicinal chemistry letters, , Dec-15, Volume: 19, Issue:24, 2009
Development of the renal glucose reabsorption inhibitors: a new mechanism for the pharmacotherapy of diabetes mellitus type 2.Journal of medicinal chemistry, , Apr-09, Volume: 52, Issue:7, 2009
Discovery of dapagliflozin: a potent, selective renal sodium-dependent glucose cotransporter 2 (SGLT2) inhibitor for the treatment of type 2 diabetes.Journal of medicinal chemistry, , Mar-13, Volume: 51, Issue:5, 2008
The Race to Bash NASH: Emerging Targets and Drug Development in a Complex Liver Disease.Journal of medicinal chemistry, , 05-28, Volume: 63, Issue:10, 2020
Synthetic strategy and SAR studies of C-glucoside heteroaryls as SGLT2 inhibitor: A review.European journal of medicinal chemistry, , Dec-15, Volume: 184, 2019
Sodium-glucose cotransporter 2 (SGLT-2) inhibitors: a new antidiabetic drug class.MedChemComm, , Aug-01, Volume: 9, Issue:8, 2018
Design, synthesis and biological evaluation of nitric oxide releasing derivatives of dapagliflozin as potential anti-diabetic and anti-thrombotic agents.Bioorganic & medicinal chemistry, , 08-07, Volume: 26, Issue:14, 2018
Discovery of Ipragliflozin (ASP1941): a novel C-glucoside with benzothiophene structure as a potent and selective sodium glucose co-transporter 2 (SGLT2) inhibitor for the treatment of type 2 diabetes mellitus.Bioorganic & medicinal chemistry, , May-15, Volume: 20, Issue:10, 2012
The Race to Bash NASH: Emerging Targets and Drug Development in a Complex Liver Disease.Journal of medicinal chemistry, , 05-28, Volume: 63, Issue:10, 2020
Sodium-glucose cotransporter 2 (SGLT-2) inhibitors: a new antidiabetic drug class.MedChemComm, , Aug-01, Volume: 9, Issue:8, 2018
Design, synthesis and biological evaluation of nitric oxide releasing derivatives of dapagliflozin as potential anti-diabetic and anti-thrombotic agents.Bioorganic & medicinal chemistry, , 08-07, Volume: 26, Issue:14, 2018
The Race to Bash NASH: Emerging Targets and Drug Development in a Complex Liver Disease.Journal of medicinal chemistry, , 05-28, Volume: 63, Issue:10, 2020
Synthetic strategy and SAR studies of C-glucoside heteroaryls as SGLT2 inhibitor: A review.European journal of medicinal chemistry, , Dec-15, Volume: 184, 2019
Design, synthesis and biological evaluation of nitric oxide releasing derivatives of dapagliflozin as potential anti-diabetic and anti-thrombotic agents.Bioorganic & medicinal chemistry, , 08-07, Volume: 26, Issue:14, 2018
(1S)-1,5-anhydro-1-[5-(4-ethoxybenzyl)-2-methoxy-4-methylphenyl]-1-thio-D-glucitol (TS-071) is a potent, selective sodium-dependent glucose cotransporter 2 (SGLT2) inhibitor for type 2 diabetes treatment.Journal of medicinal chemistry, , Apr-22, Volume: 53, Issue:8, 2010
The Race to Bash NASH: Emerging Targets and Drug Development in a Complex Liver Disease.Journal of medicinal chemistry, , 05-28, Volume: 63, Issue:10, 2020
Synthetic strategy and SAR studies of C-glucoside heteroaryls as SGLT2 inhibitor: A review.European journal of medicinal chemistry, , Dec-15, Volume: 184, 2019
Design, synthesis and biological evaluation of nitric oxide releasing derivatives of dapagliflozin as potential anti-diabetic and anti-thrombotic agents.Bioorganic & medicinal chemistry, , 08-07, Volume: 26, Issue:14, 2018
Discovery of a Potent, Selective Renal Sodium-Dependent Glucose Cotransporter 2 (SGLT2) Inhibitor (HSK0935) for the Treatment of Type 2 Diabetes.Journal of medicinal chemistry, , 05-25, Volume: 60, Issue:10, 2017
C-Aryl 5a-carba-β-d-glucopyranosides as novel sodium glucose cotransporter 2 (SGLT2) inhibitors for the treatment of type 2 diabetes.Bioorganic & medicinal chemistry, , Jul-01, Volume: 20, Issue:13, 2012
Synthetic strategy and SAR studies of C-glucoside heteroaryls as SGLT2 inhibitor: A review.European journal of medicinal chemistry, , Dec-15, Volume: 184, 2019
Sodium-glucose cotransporter 2 (SGLT-2) inhibitors: a new antidiabetic drug class.MedChemComm, , Aug-01, Volume: 9, Issue:8, 2018
Discovery of a Potent, Selective Renal Sodium-Dependent Glucose Cotransporter 2 (SGLT2) Inhibitor (HSK0935) for the Treatment of Type 2 Diabetes.Journal of medicinal chemistry, , 05-25, Volume: 60, Issue:10, 2017
Synthetic strategy and SAR studies of C-glucoside heteroaryls as SGLT2 inhibitor: A review.European journal of medicinal chemistry, , Dec-15, Volume: 184, 2019
Design, synthesis and biological evaluation of nitric oxide releasing derivatives of dapagliflozin as potential anti-diabetic and anti-thrombotic agents.Bioorganic & medicinal chemistry, , 08-07, Volume: 26, Issue:14, 2018
Discovery of tofogliflozin, a novel C-arylglucoside with an O-spiroketal ring system, as a highly selective sodium glucose cotransporter 2 (SGLT2) inhibitor for the treatment of type 2 diabetes.Journal of medicinal chemistry, , Sep-13, Volume: 55, Issue:17, 2012
Enables
This protein enables 5 target(s):
Target | Category | Definition |
low-affinity glucose:sodium symporter activity | molecular function | Enables the transfer of a solute or solutes from one side of a membrane to the other according to the reaction: glucose(out) + Na+(out) = glucose(in) + Na+(in). In low-affinity transport the transporter is able to bind the solute only if it is present at very high concentrations. [TC:2.A.21.3.-] |
glucose:sodium symporter activity | molecular function | Enables the transfer of a solute or solutes from one side of a membrane to the other according to the reaction: glucose(out) + Na+(out) = glucose(in) + Na+(in). [TC:2.A.21.3.-] |
protein binding | molecular function | Binding to a protein. [GOC:go_curators] |
alpha-glucoside transmembrane transporter activity | molecular function | Enables the transfer of alpha-glucosides from one side of a membrane to the other. Alpha-glucosides are glycosides in which the sugar group is a glucose residue, and the anomeric carbon of the bond is in an alpha configuration. [GOC:jl, GOC:mtg_transport, http://www.biochem.purdue.edu/, ISBN:0198506732, ISBN:0815340729] |
D-glucose transmembrane transporter activity | molecular function | Enables the transfer of the D-enantiomer of the hexose monosaccharide glucose from one side of a membrane to the other. [GOC:jid, GOC:jsg, GOC:mah] |
Located In
This protein is located in 4 target(s):
Target | Category | Definition |
plasma membrane | cellular component | The membrane surrounding a cell that separates the cell from its external environment. It consists of a phospholipid bilayer and associated proteins. [ISBN:0716731363] |
membrane | cellular component | A lipid bilayer along with all the proteins and protein complexes embedded in it and attached to it. [GOC:dos, GOC:mah, ISBN:0815316194] |
apical plasma membrane | cellular component | The region of the plasma membrane located at the apical end of the cell. [GOC:curators] |
extracellular exosome | cellular component | A vesicle that is released into the extracellular region by fusion of the limiting endosomal membrane of a multivesicular body with the plasma membrane. Extracellular exosomes, also simply called exosomes, have a diameter of about 40-100 nm. [GOC:BHF, GOC:mah, GOC:vesicles, PMID:15908444, PMID:17641064, PMID:19442504, PMID:19498381, PMID:22418571, PMID:24009894] |
Active In
This protein is active in 1 target(s):
Target | Category | Definition |
plasma membrane | cellular component | The membrane surrounding a cell that separates the cell from its external environment. It consists of a phospholipid bilayer and associated proteins. [ISBN:0716731363] |
Involved In
This protein is involved in 7 target(s):
Target | Category | Definition |
alpha-glucoside transport | biological process | The directed movement of alpha-glucosides into, out of or within a cell, or between cells, by means of some agent such as a transporter or pore. Alpha-glucosides are glycosides in which the sugar group is a glucose residue, and the anomeric carbon of the bond is in an alpha configuration. [GOC:jl, ISBN:0198506732, PMID:9919658] |
carbohydrate metabolic process | biological process | The chemical reactions and pathways involving carbohydrates, any of a group of organic compounds based of the general formula Cx(H2O)y. [GOC:mah, ISBN:0198506732] |
hexose transmembrane transport | biological process | The process in which hexose is transported across a membrane. Hexoses are aldoses with a chain of six carbon atoms in the molecule. [GOC:vw] |
renal glucose absorption | biological process | A renal system process in which glucose is taken up from the collecting ducts and proximal and distal loops of the nephron. In non-mammalian species, absorption may occur in related structures. [GOC:yaf, PMID:11269503] |
glucose import across plasma membrane | biological process | The directed movement of glucose from outside of a cell, across the plasma membrane and into the cytosol. [GOC:dos] |
sodium ion import across plasma membrane | biological process | The directed movement of sodium ions from outside of a cell, across the plasma membrane and into the cytosol. [GOC:dos] |
sodium ion transport | biological process | The directed movement of sodium ions (Na+) into, out of or within a cell, or between cells, by means of some agent such as a transporter or pore. [GOC:ai] |